Clinical Trial Update: Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias [Phase 2]

View source ↗

Summary

This clinical trial update announces a Phase 2 study evaluating selinexor and pacritinib in JAK inhibitor‑naïve myelofibrosis patients with cytopenias; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Pacritinib (pacritinib)
• Selinexor (selinexor)

Snippet

Sponsor: John Mascarenhas | Conditions: Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Status: NOT_YET_RECRUITING